Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
YMAT
J-Star Holding Co., Ltd. Ordinary Shares
Produces medical device components used in healthcare applications, reflecting a direct product line.
|
$16.48M |
$0.94
-2.93%
|
|
CURX
Curanex Pharmaceuticals Inc Common Stock
Lead candidate Phyto-N targets inflammatory diseases, placing CURX in the Biotech - Immunology Therapeutics space.
|
$16.26M |
$0.65
-4.03%
|
|
CTXR
Citius Pharmaceuticals, Inc.
LYMPHIR is a targeted oncology immunotherapy for CTCL, representing a core commercial product.
|
$16.26M |
$1.50
-5.38%
|
|
ATHA
Athira Pharma, Inc.
ATH-1105 is described as an orally available, brain-penetrant small molecule developed for ALS, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$16.22M |
$4.06
-2.29%
|
|
KNW
Know Labs, Inc.
Core product: KnowU CGM wearable and glucose monitoring device.
|
$16.05M |
$2.14
|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
Sonnet's core pipeline is oncology-focused immunotherapies (e.g., SON-1010 IL-12) leveraging the FHAB platform.
|
$15.89M |
$4.16
-17.23%
|
|
CRIS
Curis, Inc.
Curis's core business is oncology-focused biotech developing cancer therapies, anchored by emavusertib.
|
$15.59M |
$1.49
-0.34%
|
|
CODX
Co-Diagnostics, Inc.
Co-Dx PCR Pro instrument is a diagnostic equipment product directly manufactured by the company.
|
$15.51M |
$0.41
-10.28%
|
|
APLM
Apollomics, Inc.
The company is a biotechnology oncology-focused firm actively developing cancer therapies (vebreltinib and apolecylin) with multiple clinical programs.
|
$15.36M |
$14.00
+0.21%
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
VisiRose EyeCo focuses on ophthalmic topical RBS (PV-305) for infectious keratitis, an ophthalmic drug product.
|
$15.32M |
$0.07
|
|
VSEE
VSee Health, Inc.
Healthcare Services & Facilities; telehealth services delivered to healthcare providers.
|
$15.27M |
$1.05
+8.21%
|
|
PRPH
ProPhase Labs, Inc.
BE-Smart diagnostic test and RUO/LDT commercialization imply laboratory testing and advisory services.
|
$15.11M |
$0.32
-11.36%
|
|
FBLG
FibroBiologics, Inc. Common Stock
Core business is fibroblast-based cell therapies (CYWC628, CYMS101, CybroCell) in regenerative medicine; directly matches Biotech - Cell Therapy.
|
$15.05M |
$0.39
+0.28%
|
|
MRAI
Marpai, Inc.
PBMs (Pharmacy Benefit Managers) theme reflecting MarpaiRx's prescription cost management objectives.
|
$14.94M |
$1.45
|
|
ADAP
Adaptimmune Therapeutics plc
Adaptimmune develops engineered T-cell therapies (cell therapy) for cancer, including TECELRA and lete-cel.
|
$14.58M |
$0.06
+2.91%
|
|
AMS
American Shared Hospital Services
AMS is directly operating outpatient radiation therapy centers (Direct Patient Services) in Rhode Island, Puebla, and other locations.
|
$14.58M |
$2.24
-0.88%
|
|
PPCB
Propanc Biopharma, Inc.
Propanc Biopharma is a development-stage biotechnology company focusing on oncology therapies, making PRP its core candidate.
|
$14.40M |
$1.10
-11.29%
|
|
TRAW
Traws Pharma, Inc.
Company is developing Antiviral Small-Molecule Therapeutics (ratutrelvir) for COVID-19 as a core antiviral program.
|
$14.30M |
$2.41
-6.23%
|
|
LPCN
Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
|
$14.23M |
$2.62
-1.50%
|
|
UEEC
United Health Products, Inc.
CelluSTAT is a surgical hemostatic device used in operative settings, categorizing the company as a Surgical Equipment manufacturer.
|
$14.18M |
$0.06
|
|
EKSO
Ekso Bionics Holdings, Inc.
Product portfolio includes Ekso Indego Personal and EksoNR, both medical devices used for rehabilitation and mobility assistance.
|
$14.08M |
$5.06
-6.12%
|
|
AYTU
Aytu BioPharma, Inc.
AYTU's core ADHD portfolio comprises oral small-molecule therapeutics (Adzenys XR-ODT, Cotempla XR-ODT) and Karbinal ER, fitting the 'Oral Small Molecule Therapeutics' category.
|
$14.01M |
$2.20
-3.08%
|
|
MRM
MEDIROM Healthcare Technologies Inc.
MOTHER Bracelet and related biometric sensing capabilities align with Medical Devices & Biometrics.
|
$13.81M |
$1.95
-5.34%
|
|
ALUR
Allurion Technologies Inc.
Allurion Balloon is a swallowable medical device used for weight management.
|
$13.80M |
$1.81
-2.16%
|
|
QURT
Quarta-Rad, Inc.
Geiger counters and radiation-detection devices are diagnostic/instrumentation equipment, mapping to Diagnostic Equipment.
|
$13.79M |
$0.90
|
|
AIMD
Ainos, Inc.
VELDONA human therapeutic programs target rare diseases, aligning with Biotech - Rare Diseases.
|
$13.70M |
$3.34
+1.21%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN310 is a monoclonal antibody therapeutic targeting toxic amyloid-beta oligomers for Alzheimer's disease.
|
$13.57M |
$0.42
|
|
NVNO
enVVeno Medical Corporation
NVNO designs and manufactures medical devices, including implantable bioprosthetic venous valves and related biometrics/sensing technology.
|
$13.57M |
$0.70
-0.88%
|
|
CFOO
China Foods Holdings Ltd.
The company provides customized wellness consultation programs and related services.
|
$13.45M |
$0.66
|
|
PFHO
Pacific Health Care Organization, Inc.
PFHO provides workers' compensation cost containment services, including healthcare provider network access and case management, within the healthcare services ecosystem.
|
$13.44M |
$1.05
|
|
INTS
Intensity Therapeutics, Inc.
Company develops oncology-focused therapeutics (INT230-6.00) and operates in Biotech - Oncology.
|
$13.43M |
$0.63
-13.53%
|
|
MDXH
MDxHealth S.A.
MDxHealth's portfolio includes liquid-based diagnostic tests (Select mdx, Resolve mdx, ExoDx) that fit the Liquid Biopsy category.
|
$13.43M |
$4.90
-0.41%
|
|
OSRH
OSR Holdings, Inc.
VAXIMM's lead oncology immunotherapy candidate positions OSRH in the Biotech - Oncology space.
|
$13.07M |
$0.65
-4.31%
|
|
EDSA
Edesa Biotech, Inc.
EB06 is an anti-CXCL10 monoclonal antibody therapeutic directly developed by Edesa for vitiligo, representing a direct monoclonal antibody product.
|
$13.06M |
$1.80
-2.96%
|
|
PHGE
BiomX Inc.
BiomX leverages a drug delivery platform (BOLT) to rapidly assemble phage cocktails and targeted therapies.
|
$12.93M |
$0.48
-2.31%
|
|
LGVN
Longeveron Inc.
LGVN's lead candidate laromestrocel is a mesenchymal stem cell (MSC) therapy, directly aligning with Biotech - Cell Therapy.
|
$12.51M |
$0.83
-1.00%
|
|
BTAI
BioXcel Therapeutics, Inc.
BXCL501 is a small-molecule drug delivered as an oral dissolving film; fits 'Oral Small Molecule Therapeutics'.
|
$12.41M |
$1.95
-4.88%
|
|
HIGR
Hi-Great Group Holding Company
KRAS gene license places HIGR in Biotech - Oncology, an oncology-focused biotech asset.
|
$12.30M |
$0.12
|
|
BFRG
Bullfrog AI Holdings, Inc. Common Stock
Engages in external collaborations/partnerships to provide AI-driven drug development services, akin to CRO-type engagements.
|
$12.05M |
$1.16
-9.38%
|
|
SNSE
Sensei Biotherapeutics, Inc.
Solnerstotug is a monoclonal antibody therapeutic targeting VISTA, aligning with Monoclonal Antibody Therapeutics.
|
$11.56M |
$9.15
-0.22%
|
Showing page 33 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
